CLINICAL ROLE -
Economic Model of Granulocyte Colony-Stimulating Factors for Patients Receiving Chemotherapy
For US payers, pegfilgrastim is a less-expensive choice than daily filgrastim for reducing the risk of febrile neutropenia in patients receiving myelosuppressive chemotherapy.
Read More